-
Ab179376-5mgColtuximab (anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab177903-100μgCSL311 (anti-CSF2Rb) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis.
-
Ab177903-10mgCSL311 (anti-CSF2Rb) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis.
-
Ab177903-1mgCSL311 (anti-CSF2Rb) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis.
-
Ab177903-5mgCSL311 (anti-CSF2Rb) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis.
-
Ab179378-100μgDivozilimab (anti-CD20) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab (anti-CD20) can be used for multiple sclerosis research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab179378-10mgDivozilimab (anti-CD20) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab (anti-CD20) can be used for multiple sclerosis research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab179378-1mgDivozilimab (anti-CD20) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab (anti-CD20) can be used for multiple sclerosis research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab179378-5mgDivozilimab (anti-CD20) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab (anti-CD20) can be used for multiple sclerosis research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab177870-100μgFR104 (anti-CD28) is an antibody targeting CD28.
-
Ab177870-10mgFR104 (anti-CD28) is an antibody targeting CD28.
-
Ab177870-1mgFR104 (anti-CD28) is an antibody targeting CD28.